• The Battle of 1498 | Alternet
    https://www.alternet.org/personal-health/battle-1498

    Hepatitis C is a blood virus that affects 3.5 million Americans and kills more of them than every other virus combined. So when $62 million in government basic research led to the direct-action drug sofosbuvir, which successfully treats the disease, Hep C advocates thought global eradication might be at hand.
    Report Advertisement

    Then something awful happened: the patent-and-profit system worked exactly as designed.

    In 2011, the California-based drug giant Gilead bought the small bio-med company then in the process of bringing sofosbuvir through trials. When Gilead introduced sofosbuvir to market a few years later, it came with a price tag upwards of $100,000; even with discounts, the drug was priced well beyond the reach of most people. It also strained and busted Medicaid budgets across the country.

    Gilead and Janssen, the other company selling patented Hep C treatments, have since made more than $70 billion selling the new Hep C drugs, which happen to be incredibly cheap to produce. How cheap? So cheap, one study estimates they can be produced for between $62 and $216; another study, conducted at Liverpool University, places the cost below $100.

    Khanna continued, “The Hep C drugs present a pretty simple moral issue that highlights the need for reform. When the vast majority of scientific research in this country is being done at universities with NIH funding supported by taxpayer money, we shouldn’t be privatizing the gains. Millions of people need these drugs. We need to prioritize the public good.”

    #Big_Pharma #Hépatite_C #Brevets #Propriété_intellectuelle

  • U.S. Government Lifts Ban on Making Viruses More Deadly and Transmissible | Alternet
    https://www.alternet.org/personal-health/us-government-lifts-ban-making-viruses-more-deadly-and-transmissible?akid=

    Or rather, it did until Tuesday, when the U.S. government announced it was lifting a three-year ban on federal funding for experiments that alter viruses to make them even deadlier.

    “Gain-of-function” research, in which scientists make pathogens more powerful or easily transmissible, is aimed at preventing disease outbreaks by better understanding how they might occur. The studies allow scientists, working in a highly controlled environment, to learn how a flu virus might mutate into a superbug capable of killing millions—a sort of game of wits played to gain insight into nature’s unpredictability. The ultimate goal is to proactively create vaccines, medications and other solutions to stop contagion in its tracks.

    The new National Institutes of Health policy reverses a 2014 Obama administration funding ban on gain-of-function research projects specifically involving all forms of the influenza virus, Middle East respiratory syndrome (MERS), and severe acute respiratory syndrome (SARS). The new rules would extend beyond those viruses, “apply[ing] to any pathogen that could potentially cause a pandemic,” according to the New York Times. “For example, they would apply to a request to create an Ebola virus transmissible through the air.”

    Possibly aware that this sounds like the prologue to a very hacky horror movie, the NIH accompanied its announcement with a list of criteria that proposals must meet before funding will be granted. According to those terms, a panel will only greenlight projects if the work promises to yield practical solutions, such as an effective antiviral treatment; the research benefits must sufficiently outweigh the risks; and researchers must prove their experiment outcomes cannot be obtained using safer methodologies. Contenders will also have to prove their researchers and facilities “have the capacity to do the work safety and securely and to respond rapidly if there are any accidents, protocol lapses, or security breaches.”

    “We have a responsibility to ensure that research with infectious agents is conducted responsibly, and that we consider the potential biosafety and biosecurity risks associated with such research,” NIH director Francis S. Collins said in a statement. “I am confident that the thoughtful review process...will help to facilitate the safe, secure, and responsible conduct of this type of research in a manner that maximizes the benefits to public health.”

    Despite those reassurances, critics continue to express concern about potential mishaps. There’s some precedent for this. In 2014, CNN reported that dozens of workers at the CDC had been accidentally exposed to anthrax, while others had mishandled samples of the bacteria. No staff were found to be infected by the disease after prolonged monitoring. A Vice Motherboard report notes that between “2003 and 2009, there were 395 events reported that could have resulted in exposure to toxic agents, although this resulted in just seven infections.”

    Harvard epidemiologist Marc Lipsitch offered tepid support, telling the Times the approval panels are "a small step forward,” but cautioning that gain-of-function experiments “have given us some modest scientific knowledge and done almost nothing to improve our preparedness for pandemics, and yet risked creating an accidental pandemic.”

    Conversely, Stony Brook University president and biomedical researcher Samuel Stanley worries that the NIH decision, after three years of funding prohibition in this area, may be too little and just a wee bit too late.

    “There has been increased scrutiny of laboratories working in this area, which can lead to an even more robust culture of safety,” Stanley told NPR. “But I also fear that the moratorium may have delayed vital research. That could have long lasting effects on the field. I believe nature is the ultimate bioterrorist and we need to do all we can to stay one step ahead.”

    Comment çà « trop tard » ? Dans la compétition d’hubris entre chercheur peut-être... pas dans la sécurité de la planète. Quand j’entends « biosécurité », je pense « bioguerre », je ne sais pas pourquoi...

    #Hubris #Virus #Biosécurité

  • Why Should Taxpayers Pay for the Opioid Crisis When Pharma Caused It? | Alternet
    https://www.alternet.org/personal-health/why-should-taxpayers-pay-opioid-crisis-when-pharma-caused-it

    As everyone today knows, opioid narcotics like fentanyl, hydrocodone, hydromorphone, morphine and oxycodone have created a toxic epidemic in the United States with at least 100 daily overdose deaths. This happened because Pharma paid off doctors, medical associations and federal lawmakers to loosen opioid regulations.

    There was a reason narcotics were traditionally limited to severe pain cases, not “everyday” pain—they are addicting and can kill, as we are now seeing. But Pharma—especially the Sackler family’s Purdue which makes OxyContin—banked on the fact that younger doctors and patients did not remember why narcotics were so heavily restricted. They were right.

    As new Pharma-driven prescribing guidelines were drafted and the industry-appeasing FDA waved new pills and patches through despite daily deaths, brazen “pill mills” and “Oxy docs” popped up, as did legions of addicts. Soon “opioid addiction” treatment clinics popped up to play the other side of the street—the addictions caused by the pill mills—further enriching Pharma.

    Not only can narcotics like the popular OxyContin, Vicodin, Percocet and the fentanyl patch lead to coma, respiratory depression, shock, pulmonary edema and death, but studies suggest they can increase a body’s sensitivity to pain and make pain worse—a phenomenon called opioid-induced hyperalgesia. The drugs also cause constipation, hormonal derangement and negative mental changes.

    #Opioides #Big_Pharma #Voyoucratie